Orphan drugs and the NHS: should we value rarity?

被引：151

作者：

McCabe, C ^{[1
]}

Claxton, K

Tsuchiya, A

机构：

[1] Univ Sheffield, Sch Hlth & Related Res, White Rose Initiat Hlth Technol Assessment Hlth E, Sheffield S1 4DA, S Yorkshire, England

[2] Univ York, White Rose Initiat Hlth Technol Assessment, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England

来源：

BRITISH MEDICAL JOURNAL | 2005年 / 331卷 / 7523期

关键词：

D O I：

10.1136/bmj.331.7523.1016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1016 / 1019

页数：4

共 15 条

[1]

BOSENQUET N, 2003, PHARM DEV REG, V1, P151

[2] A rational framework for decision making by the National Institute for Clinical Excellence (NICE) [J].

Claxton, K ;

Sculpher, M ;

Drummond, M .

LANCET, 2002, 360 (9334) :711-715

[3]

*DEP HLTH, NAT DES FUND TREATM

[4]

DEVARAX A, 2004, STUD ORPH DRUGS PHAS

[5]

*FOOD DRUG ADM, OPH DRUG ACT AM

[6] SETTING HEALTH-CARE PRIORITIES IN OREGON - COST-EFFECTIVENESS MEETS THE RULE OF RESCUE [J].

HADORN, DC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (17) :2218-2225

[7] QALYFYING THE VALUE OF LIFE [J].

HARRIS, J .

JOURNAL OF MEDICAL ETHICS, 1987, 13 (03) :117-123

[8] Explaining the ''identifiable victim effect'' [J].

Jenni, KE ;

Loewenstein, G .

JOURNAL OF RISK AND UNCERTAINTY, 1997, 14 (03) :235-257

[9] The Rule of Rescue [J].

McKie, J ;

Richardson, J .

SOCIAL SCIENCE & MEDICINE, 2003, 56 (12) :2407-2419

[10]

*NAT I CLIN EXC, 2003, GUID METH HLTH TECHN

← 1 2 →